Traws Pharma
TRAW
21 hedge funds and large institutions have $1.77M invested in Traws Pharma in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 8 closing their positions.
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
17% more funds holding
Funds holding: 18 → 21 (+3)
0.36% less ownership
Funds ownership: 0.36% → 0.01% (-0.36%)
59% less capital invested
Capital invested by funds: $4.29M → $1.77M (-$2.52M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$932K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$466K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$177K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$67K |
| 5 |
QP
Quilter Plc
London,
United Kingdom
|
+$66.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$3.35M |
| 2 |
Renaissance Technologies
New York
|
-$247K |
| 3 |
MA
MYDA Advisors
Woodmere,
New York
|
-$73K |
| 4 |
KC
Kepos Capital
New York
|
-$49K |
| 5 |
Creative Planning
Overland Park,
Kansas
|
-$17K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Wells Fargo
San Francisco,
California
| – | +$157 | +1 | New |
|
TRAW Hedge Fund Activity: Q1 2020 in Review
21 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2020, worth a combined $1.77M — down 59% from $4.29M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TRAW positions and 8 closed out — a net gain of 3 holders — while 5 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, adding an estimated $932K. The largest seller was Sabby Management, exiting entirely with an estimated $3.35M sold.
- 21 institutional investors held Traws Pharma (TRAW) as of Q1 2020, up from 18 in Q4 2019.
- Funds reported $1.77M of Traws Pharma stock for Q1 2020, down 59% quarter-over-quarter.
- 11 funds opened new Traws Pharma positions in Q1 2020 and 8 closed out, a net change of +3 holders.
- The largest Traws Pharma buyer in Q1 2020 was Vanguard Group, an estimated $932K added.
- The largest Traws Pharma seller in Q1 2020 was Sabby Management, an estimated $3.35M sold.
Based on aggregated 13F filings for Q1 2020.